Karyopharm Therapeutics Inc. (KPTI) Q1 2026 Earnings Call Transcript
Karyopharm Therapeutics Q1 Earnings Call Highlights
Karyopharm Therapeutics (KPTI) Reports Q1 Loss, Beats Revenue Estimates
Karyopharm Reports First Quarter 2026 Financial Results and Completion of Phase 3 Endometrial Cancer Trial Enrollment
Karyopharm to Participate at Upcoming Investor Conferences
Karyopharm to Report First Quarter 2026 Financial Results on May 14, 2026
Karyopharm's Phase 3 SENTRY Trial in Myelofibrosis Selected for Late-Breaking Oral Presentation at ASCO 2026 Annual Meeting
Karyopharm Therapeutics (NASDAQ:KPTI) Share Price Passes Above 50 Day Moving Average – What’s Next?
Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Given Consensus Rating of “Moderate Buy” by Brokerages
Short Interest in Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Rises By 20.9%
Karyopharm Therapeutics (KPTI) Stock Jumps 6.9%: Will It Continue to Soar?
Karyopharm: Putting The Phase 3 Trial In Context
KPTI Stock Down on Mixed Phase III Myelofibrosis Combo Study Data
Karyopharm Therapeutics Inc. (KPTI) Discusses Top Line Results From Phase III SENTRY Trial in Myelofibrosis Transcript
Karyopharm Therapeutics Falls As Pivotal Trial Hits Spleen Goal But Misses Symptom Mark
Karyopharm Therapeutics' blood cancer drug meets one of two main goals in study
Karyopharm Announces $30 Million Private Placement with RA Capital
Karyopharm's Phase 3 SENTRY Trial in Myelofibrosis Met First Co-Primary Endpoint, Demonstrating Statistically Significant Improvement in Spleen Volume Reduction
Traders Purchase Large Volume of Call Options on Karyopharm Therapeutics (NASDAQ:KPTI)
Head-To-Head Comparison: Karyopharm Therapeutics (NASDAQ:KPTI) & TransCode Therapeutics (NASDAQ:RNAZ)
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Wall Street Analysts Believe Karyopharm Therapeutics (KPTI) Could Rally 56.06%: Here's is How to Trade
Karyopharm Therapeutics Inc. (KPTI) Q4 2025 Earnings Call Transcript
Karyopharm Therapeutics (KPTI) Reports Q4 Loss, Tops Revenue Estimates
Karyopharm Reports Fourth Quarter and Full Year 2025 Financial Results and Highlights Recent Company Progress
Karyopharm to Report Fourth Quarter and Full Year 2025 Financial Results on February 12, 2026
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Karyopharm Therapeutics (NASDAQ:KPTI) Shares Pass Below 50-Day Moving Average – Here’s What Happened
Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Receives Consensus Recommendation of “Moderate Buy” from Brokerages
Karyopharm Announces Preliminary Unaudited 2025 Revenue and Reiterates Expectation of Delivering Potentially Transformative Phase 3 Data in 2026
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Karyopharm to Participate in Baird's Biotech Discovery Series
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Karyopharm to Participate at the Piper Sandler 37th Annual Healthcare Conference
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Karyopharm Therapeutics Inc. (KPTI) Q3 2025 Earnings Call Transcript
Karyopharm Reports Third Quarter 2025 Financial Results and Highlights Recent Company Progress
Karyopharm to Report Third Quarter 2025 Financial Results on November 3, 2025
Karyopharm Therapeutics (KPTI)'s Technical Outlook is Bright After Key Golden Cross
Karyopharm Strengthens Balance Sheet With $100 Million Financing To Extend Cash Runway Into 2026
Karyopharm Announces Strategic Financing Transactions to Support Growth; Extends Cash Runway Into Second Quarter of 2026, Beyond Expected Top-Line Readout of Phase 3 SENTRY Trial in Myelofibrosis
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Karyopharm Therapeutics (KPTI) Moves 27.9% Higher: Will This Strength Last?
Karyopharm Announces Completion of Enrollment in the Phase 3 SENTRY Trial in Myelofibrosis
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Karyopharm Therapeutics (KPTI) Reports Q2 Loss, Lags Revenue Estimates
Karyopharm Therapeutics Inc. (KPTI) Q2 2025 Earnings Call Transcript
Karyopharm Reports Second Quarter 2025 Financial Results and Highlights Recent Company Progress
Karyopharm to Report Second Quarter 2025 Financial Results on August 11, 2025